Portage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Compliance with Nasdaq: Portage Biotech Inc. has received confirmation from Nasdaq that it has regained full compliance with listing requirements, resolving previous non-compliance issues.
Company Overview and Stock Performance: The company, focused on developing immuno-oncology therapies, is currently trading at $6.31, reflecting a 9.68% increase.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
